Table 8. Comparisons of plasma pharmacokinetic parameters of GA-S, GA-LP, and Gal-GA-LP after i.v. administration (mean ± S.D., n=5).
| Parameters | GA-S | GA-LP | Gal-GA-LP |
|---|---|---|---|
| t1/2z (h) | 5.422 ± 2.632 | 5.819 ± 0.445* | 7.487 ± 2.953* |
| CL (L h-1 kg-1) | 1.929 ± 0.446 | 0.976 ± 0.099* | 0.662 ± 0.059* |
| Vd (L kg-1) | 13.953 ± 3.000 | 8.149 ± 0.280* | 7.119 ± 2.869* |
| AUC0-t (ug h L-1) | 7373.510 ± 2243.468 | 15470.120 ± 1453.593* | 21524.930 ± 2297.092** |
| AUC0-∞ (ug h L-1) | 8493.645 ± 2238.985 | 16110.572 ± 1634.666* | 23731.974 ± 2143.466** |
| MRT0-t (h) | 3.999 ± 1.786 | 6.248 ± 0.054* | 6.616 ±0.980* |
| MRT0-∞ (h) | 6.366 ± 2.628 | 7.276 ± 0.257* | 9.440± 2.630* |
Notes: Data shown represent the mean±S.D., *, when compared with GA-S, P<0.05; **, when compared with GA-S and GA-LP, P<0.05.
Abbreviations: GA-S, glycyrrhetinic acid solvent; GA-LP, glycyrrhetinic acid liposomes; Gal-GA-LP, glycyrrhetinic acid liposomes modified with liver-targeting ligand of galactosylated derivative; T1/2z, terminal elimination half-life; CL, apparent tissue clearance; Vd, apparent volume of distribution; AUC, area under concentration-time curve; MRT, mean residence time; S.D., standard deviation; i.v., intravascular.